Halozyme Therapeutics Inc (NASDAQ:HALO)
| 42.18 BATS BZX Real-Time Price As of 3:10pm ET |  +0.93 / +2.25%Today’s Change | 25.17 Today|||52-Week Range 56.40 | -1.24% Year-to-Date |
Latest HALO News | Press Releases
| Halozyme Therapeutics (HALO) Up 4.2% Since Last Earnings Report: Can It Continue? Sep 08 / Zacks.com - Paid Partner Content |
Today’s Trading
| Previous close | 41.25 |
| Today’s open | 41.18 |
| Day’s range | 41.15 - 42.18 |
| Volume | 19,282 |
| Average volume (3 months) | 838,189 |
| Market cap | $6.0B |
Data as of 3:10pm ET, 09/16/2021
Growth & Valuation
| Earnings growth (last year) | -- |
| Earnings growth (this year) | +81.32% |
| Earnings growth (next 5 years) | +43.00% |
| Revenue growth (last year) | +36.53% |
| P/E ratio | 26.7 |
| Price/Sales | 22.58 |
| Price/Book | 37.73 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| BPMCBlueprint Medicines ... | -0.52 | -0.50% |
| TWSTTwist Bioscience Cor... | +0.28 | +0.25% |
| ---- | ||
| FATEFate Therapeutics In... | +0.44 | +0.66% |
Data as of 3:10pm ET, 09/16/2021
Financials
| Next reporting date | November 8, 2021 |
| EPS forecast (this quarter) | $0.43 |
| Annual revenue (last year) | $267.6M |
| Annual profit (last year) | $129.1M |
| Net profit margin | 48.24% |
Profile
Sector Health Technology |
Industry Biotechnology |
No executives to display |
Corporate headquarters --, -- |
Forecasts
